Effects Of Drug Compatibility Of Tanreqing On The Intracorporal Process Of Baicalin

Tanreqing is a classical prescription to treat the syndrome of retention of phlegm-heat in the lung, composed of HQ,XDF,SYJ,JYH and LQ. This paper used pharmacokinetics, intestinal absorption of rats, Caco-2 cell model and liver microsomes of rats to research the effects of drug compatibility of Tanreqing on the intracorporal process of baicalin, in order to clarify the mechanism of oral absorption and compatibility of this prescription, advanced the modernization of Tanreqing by doing secondary development of Tanreqing capsule.Grouped different drug compatibility of Tanreqing as follow:Group Jun, tw o-herbs-combined groups(Group Jun-Chen:HQ+XDF+SYJ, Group Jun-Zuo:HQ+J YH, Group Jun-Shi:HQ+LQ), one-herb-lacked groups(Group:Jun-Chen-Zuo:HQ+ XDF+SYJ+JYH, Group Jun-Chen-Shi:HQ+XDF+SYJ+LQ, Group Jun-Zuo-Shi:H Q+JYH+LQ) and Group Quanfang, researched the pharmacokinetic of each gro up. Selected the groups which can improve the absorption of baicalin significa ntly to do Single-pass intestinal perfusion (SPIP) research and the uptake and transport of baicalin based on Caco-2 cell model. And the groups which can inhibit the elimination of baicalin in rats in pharmacokinetic study to do metab olic experiment on liver microsomes of rats.The results of pharmacokinetic experiment showed that Group Quanfang and Group Jun-Chen-Zuo can increase the absorption of baicalin observably (P<0.05), and Group Jun-Chen, Group Jun-Zuo and Group Jun-Chen-Zuo can inhabit the elimination of baicalin significantly (P>0.05), And the absolute bioavailabilky of baicalin of Group Quanfang was almost 2.27 times higher than that of Group Jun. The results of SPIP showed that Group Quanfang can improve the absorption of baicalin in jejunum and ileum, and Group Jun-Chen-Zuo in jejunum observably (P<0.05). The results of Caco-2 cell research showed that Group Quanfang and Group Jun-Chen-Zuo both can increase the uptake of baicalin significantly (P<0.05),And the efflux rate was decreased(P<0.05). Meanwhile, the results of metabolic test showed that Group Jun-Chen, Group Jun-Zuo, Group Jun-Chen-Zuo and Group Quanfang all can slow down the speed of metabolism of baicalin in the liver microsomes of rats (P<0.01), meanwhile the last three groups can also inhibit the degree of metabolism (P<0.05).Different drug compatibility ways of Tanreqing had different influences on the intracorporal process of baicalin. Group Quanfang and Group Jun-Chen-Zuo can improve the absorption of baicalin, and the reason may be that the compatibility can increase the uptake of baicalin as well as reduce the efflux rate of baicalin, thus promotes absorption of baicalin in the small intestine of rats. And Group Jun-Chen, Group Jun-Zuo and Group Jun-Chen-Zuo can inhibit the elimination of baicalin, and the reason may partly be that the compatibility can inhibit the metabolism of baicalin in the liver microsomes of rats. So we presumed that the compatibility of the whole prescription was scientific and reasonable based on the results of experimental above.